The enhanced pre- and postnatal study for nonhuman primates: Update and perspectives

Birth Defects Research Part C - Embryo Today: Reviews

Volumn 93, Issue 4, 2011, Pages 324-333

  Weinbauer, Gerhard F ^a   Fuchs, Antje ^a   Niehaus, Michael ^a   Luetjens, Craig M ^a  

^a Department of Veterinary Services and Colony Management   (Germany)

Author keywords

Cynomolgus monkeys; Enhanced pre and postnatal study; Nonhuman primates

Indexed keywords

CD20 ANTIGEN; FC RECEPTOR; FC RECEPTOR GAMMA RIIIB; FIGITUMAB; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ABORTION; AMENORRHEA; B LYMPHOCYTE; BODY WEIGHT; CHRONIC TOXICITY; DEVELOPMENTAL DISORDER; DOSE CALCULATION; DRUG HALF LIFE; EMBRYO GROWTH; ENHANCED PRE AND POSTNATAL STUDY DESIGN; EXPERIMENTAL ANIMAL WELFARE; FERTILITY; FETUS GROWTH; FETUS MONITORING; GESTATION PERIOD; HUMAN; MACACA; MATING; METHODOLOGY; NONHUMAN; NONHUMAN PRIMATE; ORGANOGENESIS; PASSIVE IMMUNIZATION; PERCEPTIVE DISCRIMINATION; PERINATAL PERIOD; PLACENTAL TRANSFER; PRENATAL DRUG EXPOSURE; PRIMATE; PRIORITY JOURNAL; REVIEW; SEXUAL MATURATION; SIGNAL TRANSDUCTION; SURVIVAL; THIRD TRIMESTER PREGNANCY; TOXICITY TESTING;

ANIMAL USE ALTERNATIVES; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; GUIDELINES AS TOPIC; HUMANS; INFANT; INFANT, NEWBORN; MACACA FASCICULARIS; PRIMATES; RESEARCH DESIGN; TOXICITY TESTS;

MACACA FASCICULARIS; PRIMATES;

EID: 84856270574     PISSN: 1542975X     EISSN: 15429768     Source Type: Journal    
DOI: 10.1002/bdrc.20220     Document Type: Review

References (38)

1. Auyeung-Kim DJ, Devalaraja MN, Migone TS, Cai W, Chellman GJ. 2009. Developmental and peri-postnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator. Reprod Toxicol 28: 443-455.
2. Bowman CJ, Chmielewski G, Oneda S, Finco D, Boucher MA, Todd M. 2010. Embryo-fetal developmental toxicity of figitumumab, an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in cynomolgus monkeys. Birth Defects Res B Dev Reprod Toxicol 89: 326-338.
3. Burns-Naas LA, Hastings KL, Ladics GS, et al. 2008. What's so special about the developing immune system? Int J Toxicol 27: 223-254.
4. Buse E. 2005. Development of the immune system in the cynomolgus monkey: the appropriate model in human targeted toxicology? J Immunotoxicol 1;2: 211-216.
5. Bussiere JL, Martin P, Horner M, et al. 2009. Alternative strategies for toxicity testing of species-specific biopharmaceuticals. Int J Toxicol 28: 230-253.
6. Cappon GD, Grantham L, Chmielewski G, et al. 2011. Power analysis of learning and memory data obtained in a non-human primate ePPND study. Soc toxicol Ann Mtg, Baltimore, Poster, 2716-2201.
7. Chapman KL, Pullen N, Andrews L, Ragan I. 2010. The future of non-human primate use in mAb development. Drug Discov Today 15: 235-242.
8. Chapman K, Pullen N, Coney L, et al. 2009. Preclinical development of monoclonal antibodies: considerations for the use of non-human primates. MAbs 1: 505-516.
9. Chapman K, Pullen N, Graham M, Ragan I. 2007. Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nat Rev Drug Discov 6: 120-126.
10. Chellman GR, Bussiere JL, Makori N, et al. 2009. Developmental and reproductive toxicology studies in nonhuman primates. Birth Defects Res B Dev Reprod Toxicol 86: 446-462.
11. Council of Europe. 2007. Appendix A of the European convention for the protection 493 of vertebrate animals used for experimental and other scientific purposes (ETS 494 no. 123) - Guidelines for the accommodation and care of animals (article 5 of 495 the convention). Cons 2006;123, effective from July 15, 2007.
12. Domaingue MC, Wong P. 2011. Use of ultrasound in breeding management in a mauritian cynomolgus colony. In: Future Trends in Primate Toxicology and Biotechnology (Weinbauer, G.F., and Vogel, F., eds.), Waxmann Publisher, Muenster-New York-Munich-Berlin, pp 57-64.
13. Golub MS, Gershwin ME, Hurley LS, et al. 1985. Studies of marginal zinc deprivation in rhesus monkeys: infant behavior. Am J Clin Nutr 42: 1229-1239.
14. Golub MS, Sassenrath EN, Chapman LF. 1981. Mother-infant interaction in rhesus monkeys treated clinically with delta-9-tetrahydrocannabinol. Child Dev 52: 389-392.
15. Hendrickx AG, Makori N, Peterson P. 2000. Nonhuman primates: their role in assessing developmental effects of immunomodulatory agents. Hum Exp Toxicol 19: 219-225.
16. ICH M3(R2). 2009. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Available at:.
17. ICH S5(R2). 2000. Detection of toxicity to reproduction for medicinal products & toxicity to male fertility. Available at:.
18. ICH S6(R1) 2011. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Available at:.
19. Jarvis P, Srivastav S, Vogelwedde E, et al. 2010. The cynomolgus monkey as a model for developmental toxicity studies: variability of pregnancy losses, statistical power estimates and group size considerations. Birth Defects Res B Dev Reprod Toxicol 89: 175-187.
20. Martin PL, Breslin W, Rocca M, et al. 2009. Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals. Birth Defects Res B Dev Reprod Toxicol 86: 176-203.
21. Martin PL, Oneda S, Treacy G. 2007. Effects of an anti-TNF-alpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system. Am J Reprod Immunol 58: 138-149.
22. Martin PL, Weinbauer GF. 2010. Developmental toxicity testing of biopharmaceuticals in nonhuman primates: previous experience and future directions. Int J Toxicol 29: 552-568.
23. Pentšuk N, van der Laan JW. 2009. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol 86: 328-344.
24. Rasmussen AD, Nelson JK, Chellman GJ, et al. 2007. Use of barusiban in a novel study design for evaluation of tocolytic agents in pregnant and neonatal monkeys, including behavioural and immunological endpoints. Reprod Toxicol 23: 471-479.
25. Roopenian DC, Akilesh S. 2007. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7: 715-725.
26. Simister NE. 2003. Placental transport of immunoglobulin G. Vaccine 21: 3365-3369.
27. Spiegel A. 1930. Beobachtungen über den Sexualzyklus, die Gravidität und die Geburt bei Javamakaken. Arch Gynecol Obstet 142: 561-591.
28. Stewart J. 2008. Developmental/reproductive study design options for monoclonal antibodies. In: Weinbauer GF, Vogel F, editors. Critical contributions of primate models for biopharmaceutical drug development. Münster: Waxmann Publisher. pp. 101-112.
29. Stewart J. 2009. Developmental toxicity testing of monoclonal antibodies: an enhanced pre and postnatal design option. Reprod Toxicol 28: 220-225.
30. Tarantal AF. 2005. Ultrasound imaging in rhesus (Macaca mulatta) and long-tailed (Macaca fascicularis) macaques: reproductive and research applications. In: Wolfe-Coote, editor. The handbook of experimental animals: the laboratory primate. San Diego: Elsevier. pp. 317-349.
31. Tarantal AF, Hendrickx AG. 1988. Characterization of prenatal growth and development in the crab-eating macaque (Macaca fascicularis) by ultrasound. Anat Rec 222: 177-184.
32. Vaidyanathan A, McKeever K, Anand B, Eppler S, Weinbauer GF, Beyer JC. 2011. Developmental immunotoxicology assessment of rituximab in cynomolgus monkeys. Toxicol Sci 119: 116-125.
33. van der Laan JW, Pentsuk N. 2011. ICH S6 regulatory reproduction studies to support the use of monoclonal antibodies. In: Weinbauer GF, Vogel F, editors. Future trends in primate toxicology and biotechnology. Waxmann Publisher: Muenster, New York, Munich, Berlin. pp. 143-162.
34. van Esch E, Cline JM, Buse E, et al. 2008. Summary comparisons of female reproductive system in human and the cynomolgus monkey. Toxicol Pathol 36: 171S-172S.
35. Wehner NG, Shopp G, Osterburg I, et al. 2009. Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol 86: 144-156.
36. Weinbauer GF, Frings W, Fuchs A, Osterburg I. 2008a. Reproductive/developmental toxicity assessment of biopharmaceuticals in nonhuman primates. In: Cavagnaro JA, editor. Preclinical safety evaluation of biopharmaceuticals. A science-based approach to facilitating clinical trials. New Jersey: John Wiley & Sons, Inc. pp. 379-397.
37. Weinbauer GF, Jarvis P, Srivastav S, et al. 2011. Objective groups size determination for developmental toxicity studies in a nonhuman primate model (Macaca fascicularis). In: Weinbauer GF, Vogel F, editors. Future trends in primate toxicology and biotechnology. Muenster, New York, Munich, Berlin: Waxmann Publisher. pp. 81-94.
38. Weinbauer GF, Niehoff M, Niehaus M, et al. 2008b. Physiology and endocrinology of the ovarian cycle in macaques. Toxicol Pathol 36: 7S-23S.